Biogen Q2 Results Top Estimates; Boosts FY25 Outlook

Biogen (BIIB) reported robust second-quarter results, significantly surpassing analyst expectations with adjusted earnings of $5.47 per share against a $3.87 consensus and revenue reaching $2.65 billion, well above the $2.32 billion estimate. The biotechnology firm also raised its fiscal 2025 adjusted earnings guidance to $15.50-$16.00 per share and projected approximately flat revenue growth at constant currency, an improvement from previous expectations of a mid-single-digit decline. This updated outlook, attributed partly to the Stoke transaction and favorable foreign exchange, further exceeds Street forecasts and signals improved operational momentum for the company.

Analysis

Biogen (BIIB) delivered a robust second quarter, substantially outperforming analyst expectations and raising its full-year 2025 forecast. The company reported adjusted earnings of $5.47 per share, a 41% beat over the $3.87 consensus estimate, and a modest increase from $5.28 in the prior-year quarter. Revenue grew 7% year-over-year to $2.65 billion, significantly exceeding the $2.32 billion analysts expected. The most impactful development is the revised fiscal 2025 guidance, where adjusted EPS is now projected at $15.50-$16.00, a notable increase from the previous $14.50-$15.50 range and well above the Street's $14.64 forecast. Furthermore, the revenue outlook was upgraded from an expected mid-single-digit decline to approximately flat at constant currency. While the company attributes this improved outlook partly to a $165 million payment to Stoke and favorable foreign exchange, the magnitude of the guidance lift suggests a material improvement in the company's operational trajectory, though it explicitly noted that potential new international tariffs are not factored into this forecast.

Key Decisions for Investors

• Given the significant Q2 earnings beat and substantially raised fiscal 2025 guidance, investors should anticipate upward revisions to consensus estimates, which could act as a near-term catalyst for the stock.
• It is crucial to dissect the drivers of the improved guidance, distinguishing between the impact of fundamental business performance versus contributions from the Stoke transaction and favorable currency movements.
• While the updated outlook is positive, investors should monitor the unquantified risk from potential new international tariffs, which the company has explicitly excluded from its projections.